Similarly, zinc may contribute to GI issues like diarrhea or cramping. Many immune-supporting supplements combine vitamin C ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...

11月28日，中国国家药监局药品审评中心（CDE）官网最新公示，诺和诺德（Novo Nordisk）1类新药NNC0519-0130注射液获得临床试验默示许可，拟开发治疗2型糖尿病。根据诺和诺德公开资料，这是该公司在研的每周一次皮下注射的双靶点GIP/GLP-1受体激动剂，正在国际范围内开展2期临床，用于2型糖尿病和肥胖人群。本次为该产品首次在中国获批临床。

今天，在两次递交招股说明书后，九源基因正式登陆港交所。

Allurion's new program uses artificial intelligence guidance to help patients adhere to a well-rounded diet and exercise ...

近年来，随着 糖尿病 和肥胖症的患病率不断攀升，GLP-1类药物作为一种创新的治疗方式，在全球范围内受到越来越多的关注，成为了该治疗领域的“明星”药物。尤其是对于2型糖尿病和肥胖症患者，GLP-1类药物不仅能有效控制血糖，还能帮助减少体重，改善 生活质量 ，满足了患者对治疗效果和生活质量的双重需求。

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...